中文版正在生成中，先为你展示英文版分析。
AI核心结论
Biogen delivered a solid Q1 2026 with revenue up 1.9% YoY to $2.48B, while net income surged 32.8% to $319.5M and operating cash flow nearly tripled to $645.5M, reflecting improved profitability and working capital management.
营业收入
$2.48B
同比 ++1.93%
每股收益（基本）
$2.17
同比 ++31.52%
提交于 · 来源: SEC EDGAR 10-Q 原文
Biogen (BIIB) Q1 FY2026 营收 $2.48B，同比增长 1.9%。 净利润 $319.5M，同比增长 32.8%，稀释每股收益 $2.15。
Total revenue grew 1.9% YoY to $2,477.8M in Q1 2026 from $2,431.0M in Q1 2025, indicating stable demand across Biogen's product portfolio despite competitive pressures in the neuroscience space.
来源: Source: 10-Q Financial Data, Income Statement
Net income jumped to $319.5M from $240.5M a year ago, a 32.8% increase, suggesting meaningful operating leverage or reduced below-the-line costs such as lower interest expense or favorable tax items contributing to bottom-line expansion.
来源: Source: 10-Q Financial Data, Income Statement
Operating cash flow surged 148.9% YoY to $645.5M from $259.3M, a dramatic improvement that likely reflects better working capital management, including changes in accounts receivable, payables, or deferred revenue, alongside higher net income.
来源: Source: 10-Q Financial Data, Cash Flow Statement
Current liabilities fell 43.4% YoY to $2,998.9M from $5,297.4M, while current assets rose 20.5% to $9,190.4M, driving the current ratio to a healthy 3.06x and signaling significantly improved short-term financial flexibility.
来源: Source: 10-Q Financial Data, Balance Sheet
Long-term debt rose 38.2% YoY to $6,288.5M from $4,548.7M, suggesting Biogen may have refinanced short-term obligations into longer-dated instruments or raised new capital for strategic investments, which partially explains the sharp drop in current liabilities.
来源: Source: 10-Q Financial Data, Balance Sheet
Cost of revenue increased 5.0% YoY to $661.0M, outpacing revenue growth of 1.9%, which compresses gross margins. Sustained cost inflation in manufacturing or royalties could erode profitability if revenue growth does not accelerate.
来源: Source: 10-Q Financial Data, Income Statement
Long-term debt surged 38.2% YoY to $6.29B, materially increasing Biogen's financial leverage. Higher debt servicing costs could weigh on future net income and limit financial flexibility for R&D investment or acquisitions.
来源: Source: 10-Q Financial Data, Balance Sheet
SG&A expenses rose 6.1% YoY to $607.3M, growing more than three times faster than revenue. If this trend continues, operating leverage will be difficult to achieve and operating margins could face downward pressure.
来源: Source: 10-Q Financial Data, Income Statement
Investing cash outflows widened dramatically to -$209.5M from -$47.3M a year ago, a 342.9% increase. While this may reflect strategic investments, it raises questions about capital allocation discipline and near-term return on invested capital.
来源: Source: 10-Q Financial Data, Cash Flow Statement
With a net margin of approximately 12.9%, Biogen has limited cushion to absorb unexpected cost increases, pricing pressure on key drugs, or pipeline setbacks. Any deterioration in product revenues could quickly translate into significant earnings declines.
来源: Source: 10-Q Financial Data, Key Ratios
Q1 FY2026 实际 EPS $3.57，分析师一致预期 $2.83，超预期 +26.3%。
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
营业收入 | $2.48B | $2.43B | +1.93% |
营业成本 | $661M | $629.3M | +5.04% |
净利润 | $319.5M | $240.5M | +32.85% |
每股收益（基本） | $2.17 | $1.65 | +31.52% |
每股收益（稀释） | $2.15 | $1.64 | +31.10% |
销售及管理费用 | $607.3M | $572.5M | +6.08% |
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
总资产 | $29.48B | $28.03B | +5.17% |
流动资产 | $9.19B | $7.63B | +20.51% |
总负债 | $10.83B | $11.05B | -2.02% |
流动负债 | $3B | $5.3B | -43.39% |
长期债务 | $6.29B | $4.55B | +38.25% |
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
经营活动现金流 | $645.5M | $259.3M | +148.94% |
投资活动现金流 | $-209.5M | $-47.3M | -342.92% |
筹资活动现金流 | $-43.8M | $-23M | -90.43% |
折旧及摊销 | $204.4M | $183.2M | +11.57% |
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
净利率 | 12.9% | — | — |
总资产收益率 | 1.1% | — | — |
流动比率 | $3.065 | — | — |
Biogen reported Q1 2026 revenue of $2,477.8M, up 1.9% YoY, while net income surged 32.8% to $319.5M and diluted EPS rose 31.1% to $2.15. Operating cash flow was a standout, nearly tripling to $645.5M, reflecting strong cash generation in the quarter.
The key takeaways from Biogen's Q1 2026 results are strong bottom-line and cash flow growth despite modest top-line expansion, with net income up 32.8% and operating cash flow up 148.9% YoY. Liquidity improved sharply with the current ratio rising to 3.06x, though long-term debt increased 38.2% to $6.29B, suggesting a debt refinancing or new capital raise.
Yes, Biogen's revenue grew 1.9% YoY to $2,477.8M in Q1 2026, up from $2,431.0M in Q1 2025. While growth was modest, the company demonstrated strong profitability improvement with net income rising at a much faster pace than revenue.
Biogen's financial health appears solid in Q1 2026, with a current ratio of 3.06x indicating strong short-term liquidity and total assets of $29.5B against total liabilities of $10.8B. The main concern is the 38.2% increase in long-term debt to $6.29B, which increases financial leverage and future interest obligations.
Based on the financial data, key risks include rising cost of revenue (up 5.0% vs. revenue growth of 1.9%) compressing gross margins, a significant 38.2% increase in long-term debt to $6.29B raising leverage concerns, and SG&A expenses growing at 6.1% — more than three times the pace of revenue growth — which could pressure operating margins going forward.